The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric modulated arc therapy

Table 2 Cox proportional hazards regression analysis for overall survival

Variable	HR	95% CI	P value
Age ≥ 60 years	1.91	0.78–4.67	0.156
OTT of RT > 61 days	2.99	1.03–8.70	0.045
T3 or T4 disease	2.97	1.24–7.11	0.015
N1 or N2 disease	2.11	0.87–5.13	0.098
Pretreatment SCC Ag > 10 ng/mL	1.72	0.71–4.17	0.232
Post-treatment SCC Ag > 1.5 ng/mL	2.42	0.93–6.26	0.069
EQD2 of Point A ≥ 81 Gy	0.82	0.34–1.99	0.666
RT technique^a			0.621
VMAT	0.44	0.08–2.39	0.341
Tomotherapy	0.59	0.12–2.90	0.518

HR hazard ratio, CI confidence interval, OTT overall treatment time, RT radiation therapy, SCC Ag squamous cell carcinoma antigen, EQD2 equivalent dose in 2-Gy fractions, VMAT volumetric modulated arc therapy
^aReference category: 3DCRT, three-dimensional conformal radiation therapy

ISSN: 1748-717X